N/A Completed N=15 Treatment

Mucinex® for Treatment of Filamentary Keratitis

Filamentary Keratitis

Source: ClinicalTrials.gov NCT02859246 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2020

Primary outcomePrimary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04

Summary

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Number of Corneal Filaments	5.8; 2.1	<0.04 sig
SECONDARY Change in OSDI Score	55.6; 46.1	< 0.2

Eligibility Criteria

Inclusion Criteria

Patients with filamentary keratitis
18 years and older

Exclusion Criteria

Active ocular surface infection of any type
Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
Schirmer's test<3mm
History of hypersensitivity to Mucinex®
Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02859246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.